TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Phase 1 Recruiting 180 enrolled Treeline Biosciences, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

Timeline

Start: 2025-06-23
Primary completion: 2030-09
Completion: 2030-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TLN-121	Unknown	—	—
Subject	TLN-254	Unknown	—	—

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Summary

Timeline

Drugs

Indications